Current Status
Not Enrolled
Price
$49.99
Get Started

Course

IgA Nephropathy (Berger’s Disease)

Contact Hours Awarded: 2

Start Course
Now

Course Overview

IgA Nephropathy (Berger’s Disease)

Author: R.E. Hengsterman, MSN, RN

This course offers a comprehensive exploration of Immunoglobulin A nephropathy (IgAN), also known as Berger disease, a leading cause of glomerulonephritis and kidney failure. Learners will delve into the etiology, epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, prognosis & complications, and therapeutic management of IgAN. By utilizing a case study alongside an evaluation of the latest research, the course highlights the critical roles of early detection, teamwork across various disciplines, and the development of new treatment options. Learners will gain a deep understanding of how genetic, environmental, and immunological factors contribute to the disease, preparing them to contribute effectively to client care and ongoing advancements in nephrology. 

Course Outline

  1. Introduction 
  2. Case Study 
  3. Physical Examination 
  4. Etiology 
  5. Epidemiology 
  6. Pathophysiology 
  7. History and Physical 
  8. Differential Diagnosis 
  9. Therapeutic Management 
  10. Prognosis and Complications 
  11. Conclusion 

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In this course, we will discuss IgA Nephropathy (Berger’s Disease). It will take the average learner 120 minutes to complete and awards 2 contact hours of continuing education.

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to

  1. Discuss the pathogenesis of IgA nephropathy (IgAN) by exploring the “multi-hit” model, the role of genetic predisposition, and environmental triggers. 
  2. Recognize the clinical presentations and diagnostic features of IgAN. 
  3. Differentiate IgAN from similar conditions. 
  4. Outline therapeutic management strategies for IgAN. 
  5. Discuss prognostic factors and the importance of interprofessional collaboration in managing IgAN. 

Target Audience

  • Registered Nurses (RN)
  • Advanced Practice Registered Nurses (APRN)
  • Licensed Practical Nurses (LPN/LVN)

Requirement for Completion

  1. Enrollment in the course by the learner
  2. Read and learn all course materials
  3. Complete the course evaluation
  4. Attest and testify learning of the course materials

Accreditations + Approvals

  • American Nurses Credentialing Center (ANCC) (P0614)
  • California Board of Registered Nursing (CEP 17418)
  • Kentucky Board of Nursing (7-0090)
  • Louisiana State Board of Nursing (58)
  • New York State Department of Education (IC 208)
  • New York State Department of Education Child Abuse #80996
  • Florida Board of Nursing (50-23983)

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.

Start Course
Now

Course created on: January 28, 2025

Course Expires on: January 28, 2028

Course Offering: #599